StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Price Performance

Shares of NASDAQ FGEN opened at $0.36 on Friday. The company has a 50 day simple moving average of $0.36 and a 200 day simple moving average of $0.61. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.93. The firm has a market cap of $36.77 million, a PE ratio of -0.30 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same period in the previous year, the company posted ($0.52) EPS. As a group, research analysts anticipate that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Institutional investors have recently bought and sold shares of the stock. Franklin Street Advisors Inc. NC bought a new position in shares of FibroGen during the 2nd quarter worth approximately $89,000. Acadian Asset Management LLC boosted its position in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after purchasing an additional 860,854 shares during the last quarter. Doheny Asset Management CA bought a new position in FibroGen in the 2nd quarter valued at $48,000. XTX Topco Ltd purchased a new stake in shares of FibroGen during the 2nd quarter valued at $424,000. Finally, Sei Investments Co. raised its stake in shares of FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares during the period. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.